Literature DB >> 23270993

Kynurenic acid as an antagonist of α7 nicotinic acetylcholine receptors in the brain: facts and challenges.

Edson X Albuquerque1, Robert Schwarcz.   

Abstract

Kynurenic acid (KYNA), a major tryptophan metabolite, is a glutamate receptor antagonist, which is also reported to inhibit α7 nicotinic acetylcholine receptors (α7nAChRs). Due to variations in experimental approaches, controversy has arisen regarding the ability of KYNA to directly influence α7nAChR function. Here we summarize current concepts of KYNA neurobiology and review evidence pertaining to the proposed role of KYNA as an endogenous modulator of α7nAChRs and synaptic transmission. As dysfunction of α7nAChRs plays a major role in the pathophysiology of central nervous system disorders, elucidation of KYNA's action on this receptor subtype has significant therapeutic implications.
Copyright © 2013. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23270993      PMCID: PMC3721521          DOI: 10.1016/j.bcp.2012.12.014

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  65 in total

1.  A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists.

Authors:  M Kessler; T Terramani; G Lynch; M Baudry
Journal:  J Neurochem       Date:  1989-04       Impact factor: 5.372

2.  Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors.

Authors:  K J Swartz; M J During; A Freese; M F Beal
Journal:  J Neurosci       Date:  1990-09       Impact factor: 6.167

3.  Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid.

Authors:  M F Beal; W R Matson; K J Swartz; P H Gamache; E D Bird
Journal:  J Neurochem       Date:  1990-10       Impact factor: 5.372

4.  Kynurenic acid and quinolinic acid act at N-methyl-D-aspartate receptors in the rat hippocampus.

Authors:  A H Ganong; C W Cotman
Journal:  J Pharmacol Exp Ther       Date:  1986-01       Impact factor: 4.030

5.  Presence of kynurenic acid in the mammalian brain.

Authors:  F Moroni; P Russi; G Lombardi; M Beni; V Carlà
Journal:  J Neurochem       Date:  1988-07       Impact factor: 5.372

6.  High-affinity uptake of L-kynurenine by a Na+-independent transporter of neutral amino acids in astrocytes.

Authors:  C Speciale; K Hares; R Schwarcz; N Brookes
Journal:  J Neurosci       Date:  1989-06       Impact factor: 6.167

7.  Initial characterization of the nicotinic acetylcholine receptors in rat hippocampal neurons.

Authors:  M Alkondon; E X Albuquerque
Journal:  J Recept Res       Date:  1991

8.  On the disposition of intrahippocampally injected kynurenic acid in the rat.

Authors:  W A Turski; R Schwarcz
Journal:  Exp Brain Res       Date:  1988       Impact factor: 1.972

9.  Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism.

Authors:  S Fukui; R Schwarcz; S I Rapoport; Y Takada; Q R Smith
Journal:  J Neurochem       Date:  1991-06       Impact factor: 5.372

Review 10.  Neuropharmacology of quinolinic and kynurenic acids.

Authors:  T W Stone
Journal:  Pharmacol Rev       Date:  1993-09       Impact factor: 25.468

View more
  47 in total

1.  Urinary kynurenine as a biomarker for Parkinson's disease.

Authors:  Jia-He Bai; Ya-Li Zheng; Yong-Peng Yu
Journal:  Neurol Sci       Date:  2020-07-13       Impact factor: 3.307

2.  The BTBR Mouse, Sociability, and Reduced Glutamate Release: A Role for Endogenous Dynorphin?

Authors:  Keith Fluegge
Journal:  Neurochem Res       Date:  2017-03-16       Impact factor: 3.996

3.  Inhibition of kynurenine aminotransferase II attenuates hippocampus-dependent memory deficit in adult rats treated prenatally with kynurenine.

Authors:  Ana Pocivavsek; Greg I Elmer; Robert Schwarcz
Journal:  Hippocampus       Date:  2018-12-04       Impact factor: 3.899

4.  Astrocytic Mechanisms Involving Kynurenic Acid Control Δ9-Tetrahydrocannabinol-Induced Increases in Glutamate Release in Brain Reward-Processing Areas.

Authors:  Maria E Secci; Paola Mascia; Claudia Sagheddu; Sarah Beggiato; Miriam Melis; Andrea C Borelli; Maria C Tomasini; Leigh V Panlilio; Charles W Schindler; Gianluigi Tanda; Sergi Ferré; Charles W Bradberry; Luca Ferraro; Marco Pistis; Steven R Goldberg; Robert Schwarcz; Zuzana Justinova
Journal:  Mol Neurobiol       Date:  2018-08-27       Impact factor: 5.590

5.  Maternal immune activation in rats blunts brain cytokine and kynurenine pathway responses to a second immune challenge in early adulthood.

Authors:  Sarah M Clark; Francesca M Notarangelo; Xin Li; Shuo Chen; Robert Schwarcz; Leonardo H Tonelli
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2018-09-27       Impact factor: 5.067

Review 6.  The kynurenine pathway and the brain: Challenges, controversies and promises.

Authors:  Robert Schwarcz; Trevor W Stone
Journal:  Neuropharmacology       Date:  2016-08-07       Impact factor: 5.250

7.  Desipramine decreases expression of human and murine indoleamine-2,3-dioxygenases.

Authors:  Alexandra K Brooks; Tiffany M Janda; Marcus A Lawson; Jennifer L Rytych; Robin A Smith; Cecilia Ocampo-Solis; Robert H McCusker
Journal:  Brain Behav Immun       Date:  2017-02-16       Impact factor: 7.217

8.  Preferential Disruption of Prefrontal GABAergic Function by Nanomolar Concentrations of the α7nACh Negative Modulator Kynurenic Acid.

Authors:  Eden Flores-Barrera; Daniel R Thomases; Daryn K Cass; Ajay Bhandari; Robert Schwarcz; John P Bruno; Kuei Y Tseng
Journal:  J Neurosci       Date:  2017-07-20       Impact factor: 6.167

9.  Prenatal kynurenine exposure in rats: age-dependent changes in NMDA receptor expression and conditioned fear responding.

Authors:  Michelle L Pershing; David Phenis; Valentina Valentini; Ana Pocivavsek; Derick H Lindquist; Robert Schwarcz; John P Bruno
Journal:  Psychopharmacology (Berl)       Date:  2016-08-16       Impact factor: 4.530

Review 10.  α-Ketoglutaramate: an overlooked metabolite of glutamine and a biomarker for hepatic encephalopathy and inborn errors of the urea cycle.

Authors:  Arthur J L Cooper; Tomiko Kuhara
Journal:  Metab Brain Dis       Date:  2013-11-14       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.